Sunday, March 20, 2016 7:18:01 AM
Zusammenfassung: Vitae Pharmaceuticals Inc Outperform
Unternehmen:
Vitae Pharmaceuticals Inc Analyst:
Wedbush Morgan Securities Inc. Kursziel:
23,00 $
Rating jetzt:
Outperform Kurs*:
6,25 € Abst. Kursziel*:
268,12%
Rating update:
reiterated Kurs aktuell:
7,19 $ Abst. Kursziel aktuell:
219,89%
Analyst Name::
- KGV*:
-
* Zum Zeitpunkt der Analyse
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM